Navigation Links
Pulmonx Announces New President and CEO Michael A. Baker to Lead Interventional Pulmonology Company
Date:7/15/2009

REDWOOD CITY, Calif., July 15 /PRNewswire/ -- Pulmonx, an emerging leader in interventional pulmonology and in the development of device therapies for the treatment of emphysema announced today that Michael A. Baker has joined the company as President and CEO and that he has been elected as a member of its board of directors.

"We are very excited that Mike will be leading our company as we begin to commercialize our proprietary medical device therapies for these important indications," said Dr. Rodney Perkins, Founder and Chairman of the Board. "The strategic and leadership skills he has developed over the course of his career will be of great value to Pulmonx."

Mr. Baker's professional career comprises over two decades of executive experience in the medical device industry with much of it directly focused on the development and commercialization of new device technologies and device-based therapies. His career includes assignments with ArthroCare Corporation, where he served as the President and CEO for over 11 years, and with Medtronic, where he served for over 8 years in executive and general management assignments in both the United States and Europe. Mr. Baker holds an M.B.A. from the University of Chicago and a B.S. from the United States Military Academy at West Point.

The addition of Mike Baker follows a series of strategic developments including the receipt of FDA marketing clearance for a key new product and the completion of a successful acquisition. In early July, the company received FDA marketing clearance for the Chartis System, an assessment tool which allows physicians to make regional assessments of lung function, including quantifying inter-lobar airflow in the lungs, known as collateral ventilation. Recent research suggests that the presence of collateral ventilation may have an important impact on the effectiveness of Endobronchial Lung Volume Reduction (ELVR) therapy(1, 2). By helping physicians to identify the presence of collateral ventilation, the Chartis System may enable them to better identify patients who could benefit from endobronchial valve therapy.

The FDA clearance follows Pulmonx's recent acquisition of Emphasys Medical, which added Emphasys' Zephyr family of endobronchial valves for ELVR to the company's proprietary portfolio of diagnostic and therapeutic products. The Zephyr endobronchial valves are already CE marked and commercially available in many countries around the world. Pulmonx intends to begin international commercialization of the Chartis system as soon as it receives the CE mark.

"This is an exciting time for all of us here at Pulmonx," commented Mike Baker, President and CEO of Pulmonx. "With the completion of the acquisition of Emphasys Medical, Inc. and 510K clearance of our Chartis System, Pulmonx is poised to become a leader in the treatment of pulmonary disorders such as severe emphysema. These new technologies have the potential to cost-effectively improve the health of literally millions of patients globally and I'm extremely enthusiastic about the opportunity to lead this outstanding team as we work to commercialize these breakthrough products and build a strong franchise in Interventional Pulmonology."

About Pulmonx

Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. Pulmonx is venture funded by Montreux Ventures, MedVenture Associates, DeNovo Ventures, Latterell Ventures, Covidien Ventures and Posco Bioventures.

(1) Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.

(2) Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.


'/>"/>
SOURCE Pulmonx Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting
2. VA Announces $26 Million Construction Contract for Palo Alto
3. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results
4. CorVel Announces Earnings Release Webcast
5. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures
6. Wonderbox Technologies(R) Announces 2nd Annual Super User of the Year
7. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
8. Bayer HealthCare Announces Recipients of 2009 International Hemophilia Nursing Fellowship
9. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
10. Snoring Isn't Sexy, LLC Announces Professional Relationship with the American Sleep Apnea Association
11. Management Health Solutions, Inc. Announces Optimal Inventory Control™ (OptIC™) Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: